CCN2: a novel, specific and valid target for anti-fibrotic drug intervention

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.17, Iss.9, 2013-09, pp. : 1067-1071

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug

Current Clinical Pharmacology, Vol. 6, Iss. 2, 2011-05 ,pp. : 137-142

Bentham Science Publishers

Access to resources Recommend Favorite

Pirfenidone: A Novel Anti-fibrotic Agent and Progressive Chronic Allograft Rejection

By Dosanjh A. Ikonen T. Wan B. Morris R.E.

Pulmonary Pharmacology & Therapeutics, Vol. 15, Iss. 5, 2002-10 ,pp. : 433-437

Academic Press

Access to resources Recommend Favorite

A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor- at the translational level

By Nakazato H. Oku H. Yamane S. Tsuruta Y. Suzuki R.

European Journal of Pharmacology, Vol. 446, Iss. 1, 2002-06 ,pp. : 177-185

Elsevier

Access to resources Recommend Favorite

Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases

Current Drug Targets, Vol. 18, Iss. 10, 2017-07 ,pp. : 1214-1224

Bentham Science Publishers

Access to resources Recommend Favorite

Pirfenidone: an anti-fibrotic therapy for progressive kidney disease

By Cho Monique E Kopp Jeffrey B

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 2, 2010-02 ,pp. : 275-283

Informa Healthcare

Access to resources Recommend Favorite